Fosun Pharma is in line to exit Shanghai Henlius Biotech, which has set a price range for an offering that could raise up to $477m.

Shanghai Henlius Biotech, a China-based biotechnology developer backed by conglomerate Fosun, has filed to raise up to $477m in an initial public offering in Hong Kong, Bloomberg reported today, citing a regulatory document. Henlius will issue approximately 64.7 million shares priced at HK$49.60 to HK$57.80 ($6.30 to $7.40), and the IPO could bring in up…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.